<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539379</url>
  </required_header>
  <id_info>
    <org_study_id>6353</org_study_id>
    <nct_id>NCT04539379</nct_id>
  </id_info>
  <brief_title>Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate</brief_title>
  <official_title>Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate on Cerebral Hemodynamics of Severe Preeclampsia Patients Using Transcranial Doppler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of this study is to compare Intravenous infusion of Labetalol versus Magnesium&#xD;
      Sulfate on Cerebral Hemodynamics of Severe Preeclampsia Patients using Transcranial Doppler&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      after being informed about the study and potential risks. All patients giving written consent&#xD;
      will be randomized by double blind manner into 2 groups each one containing 30 patients ,&#xD;
      (Group M) : will be given intravenous infusion of magnesium sulfate at a dose of 4 gm&#xD;
      intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a&#xD;
      rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..&#xD;
&#xD;
      (Group L) : The patients will be given intravenous infusion of labetalol (Trandate™,)&#xD;
      available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with&#xD;
      20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the&#xD;
      infusion as required every 15 - 30min to a maximum dose of 160mg/hr.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean velocity</measure>
    <time_frame>basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration.</time_frame>
    <description>mean velocity of middle cerebral artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean end diastolic velocity</measure>
    <time_frame>basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration.</time_frame>
    <description>mean end diastolic velocity of middle cerebral artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulsatility index</measure>
    <time_frame>basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration.</time_frame>
    <description>pulsatility index of middle cerebral artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral perfusion pressure</measure>
    <time_frame>basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration.</time_frame>
    <description>cerebral perfusion pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of seizures</measure>
    <time_frame>basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration.</time_frame>
    <description>occurrence of seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for other antihypertensive drugs</measure>
    <time_frame>post-treatment one and six hours after drug administration.</time_frame>
    <description>The need for other antihypertensive drugs (nifidibine, nitroglycerine, hydralazine, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects of the study drugs</measure>
    <time_frame>post-treatment till 24 hours</time_frame>
    <description>hypotension,Bradycardia,persistent hypertension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Magnesium Sulfate</condition>
  <condition>Labetalol</condition>
  <arm_group>
    <arm_group_label>magnesium sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>labetolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>magnesium sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetolol</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>labetolol</arm_group_label>
    <other_name>(Trandate™,)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acceptance&#xD;
&#xD;
          -  21 to 45 years old.&#xD;
&#xD;
          -  mass index ≤ 35 kg/m2.&#xD;
&#xD;
          -  Singleton Pregnant female complicated with severe preeclampsia&#xD;
&#xD;
          -  Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg on two&#xD;
             occasions at least 4 hours apart&#xD;
&#xD;
          -  Thrombocytopenia (platelet count less than 100,000 )&#xD;
&#xD;
          -  Impaired liver function indicated by elevated liver enzymes (to twice the upper limit&#xD;
             normal concentration), and severe persistent right upper quadrant or epigastric pain&#xD;
             not responding to medications and not explained by another diagnosis.&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine concentration more than 1.1 mg/dL or doubling of&#xD;
             the serum creatinine concentration in the absence of other renal disease)&#xD;
&#xD;
          -  Pulmonary edema&#xD;
&#xD;
          -  New-onset headache unresponsive to medications and not accounted for by alternative&#xD;
             diagnoses&#xD;
&#xD;
          -  Visual disturbances.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preexisting heart disease&#xD;
&#xD;
          -  Known pulmonary disorders.&#xD;
&#xD;
          -  Inadequate temporal window.&#xD;
&#xD;
          -  Atrial fibrillation and any rhythm abnormality.&#xD;
&#xD;
          -  History of allergy or contraindications to either magnesium sulfate or labetolol.&#xD;
&#xD;
          -  Exposure to any of the study medications within 24 hours of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Singleton Pregnant female complicated with severe preeclampsia</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howida A kamal, M.D</last_name>
    <role>Study Director</role>
    <affiliation>zagazig U</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine,Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <state>Zagazig, Elsharkia,egypt</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>April 24, 2021</last_update_submitted>
  <last_update_submitted_qc>April 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Marwa Mohamed Medhat</investigator_full_name>
    <investigator_title>lecture of anesthesia and surgical intensive care (Principal Investigator)</investigator_title>
  </responsible_party>
  <keyword>magnesium sulfate, labetalol, severe preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

